Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 12, 2024 | -$0.03 | -$0.08 | Miss |
| Sep 30, 2024 | -$0.05 | -$0.04 | Beat |
| May 15, 2024 | -$0.07 | -$0.08 | Miss |
| Feb 14, 2024 | -$0.09 | -$0.09 | Beat |
| Nov 14, 2023 | -$0.11 | -$0.11 | Beat |
| Sep 28, 2023 | -$0.13 | -$0.10 | Beat |